dupilumab + AR101

This is a **combination therapy** of **dupilumab** (a fully human monoclonal antibody targeting the IL-4 receptor alpha subunit, thereby inhibiting IL-4 and IL-13 cytokine signaling involved in type 2 inflammation) and **AR101** (an oral biologic immunotherapy consisting of characterized peanut protein for desensitization in individuals with peanut allergy). The combination is being investigated as a means to improve both the safety and efficacy of oral immunotherapy for peanut allergy, with the hypothesis that dupilumab may reduce allergic inflammation and adverse events during desensitization, increasing tolerability and the protective immune response[1][2][3][4][5].

Other names

peanut oral immunotherapy + dupilumab